Research in the January 2023 issue of the Journal of the National Comprehensive Cancer Network finds that immunotherapy from PD-1 inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high colorectal cancer.
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
